Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) SVP Sells $36,357.39 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Thomas Andrew Rowland sold 459 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $79.21, for a total transaction of $36,357.39. Following the transaction, the senior vice president owned 38,271 shares in the company, valued at $3,031,445.91. This trade represents a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Thomas Andrew Rowland also recently made the following trade(s):

• On Wednesday, March 11th, Thomas Andrew Rowland sold 4,772 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $74.91, for a total transaction of $357,470.52.

ANI Pharmaceuticals Stock Down 2.0%

Shares of NASDAQ:ANIP opened at $78.01 on Friday. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of 19.75 and a beta of 0.46. ANI Pharmaceuticals, Inc. has a 1-year low of $56.71 and a 1-year high of $99.50. The company’s fifty day moving average is $77.29 and its two-hundred day moving average is $80.48. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm’s revenue was up 20.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on ANIP. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Guggenheim increased their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

Institutional Trading of ANI Pharmaceuticals

A number of large investors have recently modified their holdings of ANIP. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of ANI Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after acquiring an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after buying an additional 423 shares during the period. Jane Street Group LLC acquired a new position in ANI Pharmaceuticals during the 1st quarter valued at about $2,706,000. Finally, Norges Bank acquired a new position in ANI Pharmaceuticals during the 2nd quarter valued at about $625,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.